Background
Methods
Patients
HCV Genotype | No. | Age (y), range | Sex (No. of Patients, %) | Viral load (106 IU/mL), range | ALT (U/L), range | AST (U/L), range | |
---|---|---|---|---|---|---|---|
Male | Female | ||||||
1a | 12 | 39.67 (24–60) | 7 (58.33) | 5 (41.67) | 2.33 (0.01–29.90) | 58.17 (19–249) | 37.08 (10–157) |
1b | 111 | 46.81 (20–79) | 52 (47.27) | 58 (52.73) | 1.62 (0.02–46.1) | 50.15 (13–392) | 44.96 (16–453) |
2a | 89 | 50.45 (22–80) | 40 (44.94) | 49 (55.06) | 2.60 (0.00–18.10) | 49.38 (12–554) | 35.25 (15–205) |
2b | 1 | 54.00 (54–54) | 0 (100.00) | 1 (0.00) | 1.08 | 286.00 | 351.00 |
3a | 11 | 37.91 (25–53) | 8 (72.73) | 3 (27.27) | 5.52 (0.21–29.5) | 91.27 (37–340) | 50.36 (32–160) |
3b | 5 | 38.00 (23–45) | 3 (60.00) | 2 (40.00) | 1.71 (0.10–6.88) | 52.40 (58–204) | 37.00 (44–141) |
4a | 0 | ||||||
5a | 1 | 43.00 (43–43) | 2 (100.00) | 0 (0.00) | 0.00 | 0.00 | 0.00 |
6a | 1 | 25.00 (25–25) | 1 (100.00) | 0 (0.00) | 0.00 | 0.00 | 0.00 |
Z = 3.6464 | chi-squared =0.643 |
Z = 1.8797 |
Z = 0.6820 |
Z = 0.6820 | |||
P value | .067 | .836 | .113 | .605 | .605 |
DNA/RNA extraction
Quantitative real-time fluorescence PCR
Primer | IL-28B | Sequence |
---|---|---|
RT-PCR primers | rs12989760 forward: | 5′-GTCGTGCCTGTCGTGTACTGA-3′ |
rs12989760 reverse: | 5′-AGCGCGGAGTGCAATTCA-3′ | |
rs8099917 forward: | 5′-CTCCTTTTGTTTTCCTTTCTGTGA-3′ | |
rs8099917 reverse: | 5′-ACATAAAAAGCCAGCTACCAAACT-3′ | |
rs12980275 forward: | 5′-ACATGAGGTGCTGAGAGAAGTCAA-3′ | |
rs12980275 reverse: | 5′-TACCCCGGCAAATATTTAGACAC-3′ | |
Sequencing primers | rs12989760 | 5′-AGCTCCCCGAAGGCG-3′ |
rs8099917: | 5′-TCCTTTCTGTGAGCAAT-3′ | |
rs12980275: | 5′- GAAGTCAAATTCCTAGAAA −3′ |
Gene sequencing
Liver fibrosis staging
Statistical analyses
Results
HCV genotype and distribution
IL-28B genotype in patients with chronic HCV infection
Genotype | SNP | Percent | Age (y) | Sex (No. of Patients, %) | Viral Load (106 IU/mL), range | ALT (U/L), range | AST (U/L), range | |
---|---|---|---|---|---|---|---|---|
(%) | Male | Female | ||||||
IL-28B rs8099917 | TT (n = 39) | 76.47 | 48 (25–64) | 54 (52.9) | 52 (47.1) | 7.98 (0.24–72.46) | 34 (18–179) | 38 (17–203) |
TG + GG (n = 12) | 23.43 | 47 (22–58) | 21 (55.3) | 16 (44.7) | 9.25 (0.89–59.71) | 36 (28–150) | 40 (24–138) | |
IL-28B rs12979860 | CC (n = 39) | 76.47 | 49 (22–64) | 57 (52.3) | 52 (47.7) | 10.23 (1.02–68.52) | 35 (21–112) | 32 (19–143) |
CT + TT (n = 12) | 23.43 | 49 (20–58) | 18 (52.9) | 16 (47.1) | 8.72 (0.48–65.32) | 37 (19–135) | 34 (17–178) | |
IL-28B rs12980275 | AA (n = 37) | 72.55 | 47 (28–64) | 51 (51.5) | 48 (48.5) | 11.25 (1.37–66.68) | 38 (22–144) | 31 (20–123) |
AG + GG (n = 14) | 27.45 | 46 (25–59) | 24 (54.5) | 20 (45.5) | 9.67 (0.69–71.26) | 32 (19–179) | 29 (17–112) | |
Z = 0.125 | chi-squared = 0.413 |
Z = 0.579 |
Z = 0.378 |
Z = 2.143 | ||||
P value | .912 | .648 | .825 | .617 | .346 |
Correlation between HCV genotypes and antiviral efficacy
Role of IL-28B gene polymorphism in antiviral efficacy
Role of IL-28B SNP and HCV genotype in antiviral efficacy
Association of liver fibrosis staging and cirrhosis in patients with chronic HCV infection and antiviral efficacy
Variables | No. of Patients (%of Total) |
---|---|
Total number of patients | 231 |
Age ± standard deviation, y | 46.71 ± 14.34 |
Male | 113 |
Female | 118 |
APRI data | 190 (82.3) |
FIB-4 data | 190 (82.3) |
Genotype | No. of Patients (% of Total) | No. of Patients with FIB-4 > 3.25 (% of Total) | No. of Patients with APRI > 2 (% of Total) | Total SVR (%) | No. of Patients with FIB-4 > 3.25 and SVR (%) | No. of Patients with APRI > 2 and SVR (%) |
---|---|---|---|---|---|---|
1b | 90 (81.1) | 32 (16.8) | 19 (10.0) | 58 (64.4) | 19 (31.0) | 11 (30.3) |
2a | 76 (85.4) | 21 (11.1) | 12 (6.3)*
| 67 (88.1) | 11 (39.4) | 8 (50.2) |
Other | 24 (77.4) | 7 (3.7) | 8 (4.2) | 13 | ||
Total | 190 (82.3) | 60 (31.6) | 30 (20.5) | 138 (72.6) |